Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE versus OLOPATADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE versus OLOPATADINE HYDROCHLORIDE.
DIMETANE vs OLOPATADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane (brompheniramine) is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
Olopatadine hydrochloride is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits histamine release from mast cells and prevents histamine-induced effects such as increased vascular permeability and pruritus.
1-2 tablets (4-8 mg chlorpheniramine maleate) orally every 4-6 hours, not to exceed 12 tablets (48 mg) in 24 hours.
One drop of 0.1% or 0.2% ophthalmic solution in each affected eye twice daily (every 6-8 hours) for 0.1%; once daily for 0.2%.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults, necessitating twice-daily or three-times-daily dosing for continuous effect.
Terminal elimination half-life of 8–12 hours in healthy adults; prolonged in hepatic impairment (up to 18 hours)
Primarily renal excretion of metabolites, with approximately 50% of a dose excreted in urine as unchanged drug and metabolites; biliary/fecal excretion is minor (< 10%).
Primarily renal excretion (60-70% unchanged), with minor biliary/fecal elimination (~30% as metabolites)
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer